Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NEXT
Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer
- NCT03171025 ↗
- Active, not recruiting
- University of Utah
- Focused
We haven't built an HCP commentary report on NEXT (nivolumab in localized muscle-invasive bladder cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NEXT so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 8 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Open Label Single Arm Study of Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer (NEXT)
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Bladder Cancer
- Interventions
- Nivolumab
- Arms
- Nivolumab, all patients · Experimental
- Enrollment
- 200
- Primary outcomes
- Two-year rate of failure-free survival (FFS)
- Sponsor
- University of Utah with Bristol-Myers Squibb
- Start
- Jul 10, 2017
- Primary completion
- Feb 10, 2025
- Results posted
- No
- Registry record
- NCT03171025 · updated Jan 7, 2026
Publications
linked from the registry- Galarza Fortuna GM, Grass D, Maughan BL, Jain RK, Dechet C, Beck J, Schuetz E, Sanchez A, O'Neil B, Poch M, Li R, Lloyd S, Tward J, Phunrab T, Hawks JL, Swami U, Boucher KM, Agarwal N, Gupta S. Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT). J Immunother Cancer. 2025 Mar 18;13(3):e010572. doi: 10.1136/jitc-2024-010572. PubMed 40102029